Trial Profile
A Phase I Study of Gemcitabine Plus Oxaliplatin in Combination With Imatinib Mesylate (Glivec) in Patients With Gemcitabine-refractory Advanced Adenocarcinoma of the Pancreas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2012
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms RPGOG1
- 01 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2010 New trial record